Table 1.
Patient, disease, and transplantation characteristics
| Characteristics | No. (%) |
P | |
|---|---|---|---|
| Double UCB Transplantation | Single UCB Transplantation | ||
| No. of patients | 303 | 106 | |
| No. of transplantation teams | 45 | 47 | |
| Median recipient age, y (range) | 43 (16-71) | 33 (16-69) | < .0001 |
| 16-20 | 32 (11) | 27 (25) | |
| 21-30 | 53 (17) | 20 (19) | |
| 31-40 | 48 (16) | 21 (20) | |
| 41-50 | 51 (17) | 15 (14) | |
| 51-60 | 76 (25) | 14 (13) | |
| 61-71 | 43 (14) | 9 (8) | |
| Recipient CMV serostatus transplantation | .52 | ||
| Negative | 93 (31) | 35 (33) | |
| Positive | 193 (64) | 68 (64) | |
| Not reported | 17 (6) | 3 (3) | |
| Disease | .34 | ||
| Acute myeloid leukemia | 215 (71) | 70 (66) | |
| Acute lymphoblastic leukemia | 88 (29) | 36 (34) | |
| Disease status | .006 | ||
| First complete remission | 135 (45) | 38 (36) | |
| Second complete remission | 100 (33) | 31 (29) | |
| Third complete remission | 20 (7) | 5 (5) | |
| Relapse | 48 (16) | 32 (30) | |
| Donor-recipient HLA match | .07 | ||
| 6/6 | 13 (4) | 10 (9) | |
| 5/6 | 80 (26) | 33 (31) | |
| 4/6 | 210 (69) | 63 (59) | |
| Conditioning regimen | < .0001 | ||
| Myeloablative | |||
| TBI + cyclophosphamide* | 94 (31) | 49 (46) | |
| TBI + other agents** | 22 (7) | 10 (9) | |
| Busulfan + cyclophosphamide*** | 7 (2) | 8 (8) | |
| Busulfan + other agents**** | 16 (5) | 10 (9) | |
| Reduced intensity | |||
| TBI + cyclophosphamide + fludarabine† | 119 (39) | 20 (19) | |
| Busulfan + fludarabine†† | 5 (2) | 2 (2) | |
| Melphalan + fludarabine††† | 35 (12) | 5 (5) | |
| Cyclophosphamide + fludarabine†††† | 5 (2) | 2 (2) | |
| GVHD prophylaxis | < .0001 | ||
| Tacrolimus alone or with steroid | 8 (3) | 10 (9) | |
| Tacrolimus + methotrexate | 6 (2) | 9 (8) | |
| Tacrolimus + mycophenolate mofetil | 85 (28) | 20 (19) | |
| Cyclosporine alone or with steroid | 8 (3) | 19 (8) | |
| Cyclosporine + methotrexate | 1 (< 1) | 6 (6) | |
| Cyclosporine + mycophenolate mofetil | 176 (58) | 40 (38) | |
| Mycophenolate mofetil + steroid | 1 (< 1) | ||
| Not reported | 18 (6) | 2 (2) | |
| TNC cryopreserved, ×107/kg (sum of units) | < .0001 | ||
| Median dose (range) | 4.5 (2.6-15) | 3.5 (2.5-8.6) | |
| 2.5-3.0 | 18 (6) | 26 (28) | |
| 3.0-4.0 | 77 (25) | 47 (43) | |
| > 4.0 | 202 (67) | 33 (30) | |
| Not reported | 6 (2) | ||
| TNC infused, ×107/kg (sum of units) | < .0001 | ||
| Median dose (range) | 3.7 (1.8-15.8) | 2.8 (1.0-7.5) | |
| < 2.5 | 28 (9) | 30 (28) | |
| 2.5-3.0 | 49 (16) | 35 (33) | |
| 3.0-4.0 | 108 (36) | 21 (20) | |
| > 4.0 | 111 (37) | 20 (19) | |
| Not reported | 6 (2) | ||
| Year of transplantation | < .0001 | ||
| 2002-2004 | 40 (14) | 32 (30) | |
| 2005-2009 | 263 (86) | 74 (70) | |
| Median follow-up, mo (range) | 23 (3-74) | 17 (3-62) | |
TBI indicates total body irradiation; TNC, total nucleated cell dose; and UCB, umbilical cord blood.
N = 4 double UCB recipients and N = 13 single UCB recipients received ATG.
N = 4 double UCB recipients and N = 4 single UCB recipients received ATG.
N = 3 double UCB recipients and N = 6 single UCB recipients received ATG.
N = 9 double UCB recipients and N = 6 single UCB recipients received ATG.
N = 35 double UCB recipients and N = 4 single UCB recipients received ATG; TBI dose = 200 cGy
N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.
N = 30 double UCB recipients and N = 4 single UCB recipients received ATG.
N = 2 double UCB recipients and N = 1 single UCB recipients received ATG.